Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given an average rating of “Moderate Buy” by the ten research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $23.00.

Several brokerages have recently issued reports on ARCT. Roth Capital restated a “buy” rating and issued a $41.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, August 9th.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its stake in shares of Arcturus Therapeutics by 264.8% in the second quarter. Squarepoint Ops LLC now owns 50,253 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 36,479 shares in the last quarter. Corient Private Wealth LP purchased a new position in Arcturus Therapeutics in the second quarter worth $117,000. Two Sigma Securities LLC acquired a new stake in Arcturus Therapeutics in the second quarter valued at $80,000. Hsbc Holdings PLC boosted its position in shares of Arcturus Therapeutics by 7.7% during the 2nd quarter. Hsbc Holdings PLC now owns 56,895 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 4,070 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Arcturus Therapeutics during the 2nd quarter worth $229,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Up 8.5%

Shares of ARCT stock opened at $16.93 on Friday. The firm has a 50 day moving average of $10.26 and a two-hundred day moving average of $8.55. The stock has a market capitalization of $481.15 million, a PE ratio of -5.11 and a beta of 2.48. Arcturus Therapeutics has a 52 week low of $5.50 and a 52 week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The company had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Analysts expect that Arcturus Therapeutics will post -3.48 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acid medicines into targeted cells, and STARR, a self-amplifying mRNA technology intended to produce therapeutic proteins from relatively small doses of RNA.

Arcturus is developing RNA-based candidates for rare diseases, infectious diseases, and other conditions.